Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(50.0%)
Phase 1
3(50.0%)
6Total
N/A(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06413238Phase 1Not Yet Recruiting

Rationale and Design of Diabetes Management With Curcumin and Saffron (DMCS): a Randomised, Three Blind -Blind, Placebo-controlled Study

Role: collaborator

NCT02402582Not ApplicableCompleted

Effect of Family-Centered Empowerment Model

Role: collaborator

NCT03384433Phase 1Unknown

Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

Role: collaborator

NCT02432859Not ApplicableCompleted

Electrical Stimulation and Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer

Role: lead

NCT02452086Not ApplicableCompleted

Low Level Laser Therapy and Expression of VEGF, NO, VEGFR-2, HIF-1α in Diabetic Foot Ulcers

Role: lead

NCT00420134Phase 1Completed

Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial

Role: collaborator

All 6 trials loaded